Clinical trials: Prostatic Intraepithelial Neoplasia
Prostatic Intraepithelial Neoplasia
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study.
- Trial name
- NCT00028353
- Testing
- GTX-006 (Acapodene)
- Where
- 25 sites in United States
- Volunteers
- 500 people
- Sponsor
- GTx
Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
- Trial name
- NCT00106691
- Testing
- Toremifene 20 mg
- Where
- 138 sites in United States, Argentina and 1 more
- Volunteers
- 1,589 people
- Sponsor
- GTx
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG